; (B) projected costs of developing new manufacturing capabilities for active pharmaceutical ingredients not currently available domestically, as of the date of the report; and (C) projected costs of expanding existing domestic capabilities and policies, as of the date of the report, that may help establish or strengthen domestic manufacturing capacity for active pharmaceutical ingredients, excipients, key starting materials, components, functional ingredients, and finished dosage manufacturing facilities; and (2) an assessment of incentives already offered or being considered for the development or improvement of domestic capacity to manufacture active pharmaceutical ingredients, their intermediates, and their excipients, including— (A) contractual arrangements for existing domestic storage and manufacturing of active pharmaceutical ingredients; (B) guaranteed contracts for initial purchase and replenishment of essential generic medicines; and (C) other policies designed to help incentivize the relocation of manufacturing facilities to the United States or provide economic incentives for domestic production.